INmune Bio enters $65M ATM equity distribution agreement with A.G.P.

Inmune Bio, Inc.

Up to $65M of common stock may be sold from time to time through A.G.P. as sales agent.
Commission of 3.0% of gross proceeds; Company not obligated to sell any shares.
Shares offered via shelf registration effective Aug 7, 2024, with prospectus supplement dated Dec 19, 2025.
A.G.P. will use commercially reasonable efforts consistent with Nasdaq rules and state/federal law.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.